Sign In
NewsRadar

Mucosis wins Wellcome Trust award and backing from current investors

20 January 2016 10:51
By Tornado Staff

Dutch needle-free vaccines developer Mucosis has secured a €3.7 million translational fund award from the Wellcome Trust to progress its intranasal respiratory syncytial virus (RSV) vaccine, SynGEM, into phase I and IIa human clinical trials. The company also secured €2 million additional equity financing from its current investors. These funds will enable it to complete GMP manufacturing, and to advance the investigational medicinal product dossier (IMPD) submission materials for clinical trial approval in 2016.

Mucosis uses its technology platform to develop next-generation needle-free human vaccines for infectious diseases. The patient-friendly vaccines can be delivered via the nose or mouth to evoke a more natural immune response with a broader base of protection. The company is developing multiple programs for its clinical-stage Mimopath platform vaccine technology for several routes of administration including those that provide additional mucosal protection, where over 90% of pathogens enter the human body.

Mucosis’s lead product SynGEM is a stabilized recombinant vaccine delivered intranasally to prevent respiratory syncytial virus (RSV) infection. It will enter human proof-of-concept studies in 2016. The trials will be led by RSV expert Professor Peter Openshaw and Dr. Christopher Chiu of the National Heart & Lung Institute, Imperial College London.

The company has also developed PneuGEM, a vaccine to prevent diseases caused by pneumococcal bacteria, and FluGEM, a vaccine against influenza which served as a successful proof of concept for the Mimopath platform in human clinical testing.

Mucosis has raised over €20 million in funding, with key investment partners including MedSciences, BioGeneration, NOM and Utrecht Holdings.



Related stories
Massive £50 million Series B round for UK-based Cell Medica
€6.3 million Series C for Humedics’ liver function diagnostic device
Medication safety system provider Mint Solutions secures €4.4 million
Big VC rounds for Ganymed and MISSION to fight cancer
Catalan medical diagnostics company STAT-Diagnostica gets €17 million


Up
Data


25,099
Tech investments
From our Online Data Service
16,240
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 7€6.3MNanotechnology
Dec 7€21.1MInternet commerce
Dec 7€4.8MInternet commerce
Dec 7€1.8MInternet commerce
Dec 6N/AInternet commerce
Dec 6€26.0MBusiness applications
Dec 6€5.6MMedical devices

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom





About usContact usLegal Information
Copyright © 1999-2018
Emerging Technology Research Europe Inc. All rights reserved.